Table 2.
Mean (95% confidence interval) urinary tea catechin concentrations at baseline and on average during 2 months of intervention by treatment group
| Placebo | 400 mg EGCG as PPE | 800 mg EGCG as PPE | P1 | P2 | P3 | |
|---|---|---|---|---|---|---|
| EGC4 (μmol/g Cr) | ||||||
| Baseline | 0.80 (0.33,1.27) | 0.78 (0.44,1.12) | 0.84 (0.36,1.31) | 0.98 | ||
| Ave month 1–2 | 0.77 (0.39,1.15) | 2.25 (1.58,3.02) | 8.49 (5.93, 11.0) | |||
| Absolute change | −0.03 (−0.43,.36) | 1.47 (0.70,2.24) | 7.65 (5.10,10.2) | |||
| P value | 0.86 | <0.001 | <0.001 | <0.0001 | <0.0001 | |
| 4′-MeEGC4(μmol/g Cr) | ||||||
| Baseline | 0.19 (0.05,0.34) | 0.56 (0.06,1.06) | 0.38 (0.00,0.75) | 0.40 | ||
| Ave month 1–2 | 0.47 (0.03,0.91) | 7.73 (−0.5.15.9) | 10.8 (7.5, 14.0) | |||
| Absolute change | 0.27 (−0.17,0.72) | 7.16 (−1.1,15.4) | 10.4 (7.1,13.6) | |||
| P value | 0.22 | 0.086 | <0.001 | 0.013 | 0.48 | |
| EC4 (μmol/g Cr) | ||||||
| Baseline | 1.37 (0.53,2.21) | 0.74 (0.40,1.09) | 2.86 (0.92,4.80) | 0.039 | ||
| Ave month 1–2 | 1.87 (0.91,2.83) | 3.49 (2.56,4.43) | 13.2 (10.0,16.3) | |||
| Absolute change | 0.50 (−0.22,1.2) | 2.75 (1.82,3.68) | 10.33 (6.7,14.0) | |||
| P value | 0.17 | <0.001 | <0.001 | 0.0002 | <0.0001 | |
| M44 (μmol/g Cr) | ||||||
| Baseline | 0.66 (0.23,1.09) | 0.46 (0.09,0.83) | 0.34 (0.13,0.55) | 0.43 | ||
| Ave month 1–2 | 0.54 (0.22,0.86) | 1.96 (0.95,4.1) | 2.51 (0.95, 4.08) | |||
| Absolute change | −0.12 (−0.56, 0.32) | 1.50 (0.29,2.70) | 2.17 (0.59,3.76) | |||
| P value | 0.59 | 0.011 | 0.009 | 0.009 | 0.47 | |
| M64 (μmol/g Cr) | ||||||
| Baseline | 19.5 (13.2,25.8) | 15.2 (8.7,21.8) | 19.3 (11.5,27.2) | 0.60 | ||
| Ave month 1–2 | 18.8 (9.3,28.3) | 48.0 (36.1,59.8) | 57.8 (44.0,71.6) | |||
| Absolute change | −0.68 (−8.5,7.1) | 32.7 (19.0,46.4) | 38.5 (26.2,50.7) | |||
| P value | 0.86 | <0.001 | <0.001 | <0.0001 | 0.53 | |
1
P value for difference between the 3 groups at baseline (ANOVA for continuous variable, 2 df)
2
P value for difference in change between the placebo versus the two PPE groups
3
P value for difference in change between the 400 mg and 800 mg PPE groups
4
EGC=epigallocatechin; EC=epicatechin; MeEGC= 4′-O-methyl-epigallocatechin; M4= 5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone (metabolite of EGC); M6= 5-(3′,4′-dihydroxy-phenyl)-γ-valerolactone (metabolite of EC)